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INTRODUCTION
Rheumatoid arthritis (RA) is connected with substantial economic consequences both for patients and society (1) (2) (3) (4) (5) (6) (7) . The cost picture of RA has changed during the last decade, with increasing drug costs after the introduction of biological drugs. A number of clinical trials have shown that biological drugs reduce disease activity and improve quality of life (8) (9) (10) .
They are, however, 30-40 times more costly than traditional disease-modifying antirheumatic drugs, DMARDs (3) . Based on results from clinical trials, there has been an expectation that higher costs for drug treatment will partly be offset by a reduction in other healthcare consumption and increased work ability (11) (12) (13) (14) . However, recent research indicates that the effect on RA progression in real life might not be as good as reported in clinical trials (15) (16) . Data on work ability for patients prescribed biological drugs are conflicting, with reports of decreasing sick leave but also an increasing number of disability pensions (DPs) (17) (18) (19) (20) (21) (22) .
Long-term observational studies are of particular interest in evaluating the impact of biological drugs on the total costs of RA. Internationally, few longitudinal cost studies for RA that cover a part of the 2000s have been identified (15, (23) (24) , indicating a need for more comprehensive studies with a longer time perspective. Most previous cost studies in Sweden have been cohort based, focusing on partial costs and evaluating the mean annual cost per patient (25) (26) (27) (28) . Studies investigating total societal costs of RA have also been based on cohort data or calculated for one year at a time (29) (30) (31) . In Sweden, there are national registries that provide a unique opportunity to examine long-term healthcare consumption as well as work participation for the most relevant cost items.
Costs of rheumatoid arthritis 1990-2010: A register based cost-of-illness study in Sweden 4 The objectives of the present study, using comprehensive Swedish national databases, are to examine changes in the total costs for RA during 1990-2010, ten years prior to the introduction of biological drugs and ten years after, and to discuss potential reasons for changes in costs.
METHODS

Swedish Healthcare System
Sweden has a tax-financed health insurance system allowing all residents sick leave benefits when they are unable to work. After reaching a payment level for outpatient visits of 1100SEK (about €100) annually, healthcare utilisation is free of charge. Similarly, all prescribed drugs, including biological drugs, are free of charge after a payment level of 2200SEK (about €200). There were no formal restrictions on the prescription of biological drugs in Sweden 1999-2010 and usage was among the highest in Europe (32).
Cost assignment
Costs were calculated using a societal perspective, as recommended for health economic analyses in Sweden (33). Total annual costs, both direct and indirect, were calculated based on prevalence of patients with RA as the primary cause of treatment or work absence.
Direct costs included costs for inpatient and outpatient visits, surgical procedures and pharmaceuticals. Prices from healthcare pricelists were used as reasonable proxies for opportunity costs. Indirect costs comprised productivity loss due to sick leave and DP.
An important issue in the present study is to show to what extent costs for society due to RA have changed over time. One option is to simply make cost comparisons in nominal terms using current prices. This, however, does not take into account the price inflation-a euro today is worth less than a euro yesterday. A price index should be used to put nominal costs into fixed terms, providing an accurate sense of what a euro can buy today vs. yesterday, be it healthcare or something else.
In the present study, both current and fixed prices are presented. For current prices, healthcare consumption and days with sick leave or DP for each specific year were multiplied with average healthcare prices and average annual cost of labour of that year.
For fixed prices, the sum was thereafter inflation-adjusted to equal the price-level of 2010. In the present study, prices were inflation-adjusted in two ways. First with CPI, reflecting the average price changes in the economy, and secondly with a healthcare price index, reflecting the price changes in the healthcare sector.
Costs were converted to euro using the exchange rate of 2010 (1€=9.54 SEK). Registers did not cover social services and care for the elderly in the municipalities, or non-medical direct costs such as transportation, devices and home healthcare services. They were hence not included in the analysis. Costs for premature death as well as intangible costs, such as pain and suffering, were neither included due to lack of data. Table 1 depicts the included cost domains, their respective data sources and years covered. All data were derived from reliable national and regional registries except for outpatient care and sick leave during the 90s when data are missing for many years and had to be estimated.
Direct costs
Inpatient care
Complete inpatient care data, including surgical interventions, were available in the inpatient care register for the whole study period. Data was selected on number of patients, hospital admissions and days in hospital each year with RA as primary diagnosis. In 1992, a reform was implemented in Sweden that shifted responsibility for long-term and elderly care from the county councils to the municipalities. In order to avoid double counting, data for 1992 were also used as an estimate for the two previous years, 1990 and 1991. The average daily cost of internal medicine departments was used as unit cost, since cost data for rheumatology departments were limited (35-38).
Outpatient care
National data in the outpatient care register were not complete before 2005. Instead, data were derived from regional databases in the Östergötland County Council, Västra Götaland Region and the Region of Skåne, where official data linked to the diagnostic codes were available from 2000 and onwards. The total population of the three areas is equivalent to approximately 1/3 of the Swedish population, and the prevalence of RA in the three areas is similar to the national prevalence (39), suggesting that these data are an appropriate estimate for total outpatient costs. Costs for RA-related outpatient care, including non-physician service utilization and diagnostic and surgical procedures were extracted and then extrapolated to the national level by the regional populations. The number of outpatient visits per inhabitant was similar in all three areas, and furthermore, the number of visits remained stable around ninety thousand per year during the studied years.
Since outpatient data were missing for the 1990s, and outpatient visits remained unchanged during the whole decade prior to 2010, the number of visits to physicians during [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] was also assumed to be ninety thousand per year. The average cost for physician visits was used as unit cost in the 1990s (40).
Drugs
Costs for drugs prescribed to patients with RA (excluding biological drugs) were available for 
Indirect costs
The human capital method was applied, assuming that all sickness absence of people below age 65 years is associated with loss of productivity. This method implies the simplified assumption of full employment. Our data for sick leave and DP do not show whether a person was on full-or part-time sickness absence. We assumed that our population followed the average full-and part-time distribution of the general population. Accordingly, average annual income, including costs for vacation, for men and women was used. In addition, pension funding and social fees of 40%, a weighted average for blue-collar and white-collar workers, were added (Statistics Sweden; http://www.scb.se).
Sick leave
Data for sick leave days due to RA, for men and women respectively, were obtained for 
Disability pension
Data for the number of men and women with on-going RA-related DPs were obtained for 1991, 1996, 2002 and 2003-2010 (49-51) . For years when data was missing, the number of DPs for RA was calculated by multiplying all DPs with the share of DPs attributed to RA for the years with data. We assumed that all individuals with DP received pensions during the whole year. Since the vast majority of patients with DP due to RA were above 55 years of age, the average income for ages 55-65 years was used.
No ethical approval was applied for since only official statistics and public databases were used.
RESULTS
The following section describes the changes in RA-related consumption of healthcare, sick leave and DPs. Total costs are then presented in current prices, as well as in 2010 prices inflation-adjusted both with CPI and the healthcare price index.
Inpatient care
Throughout the period studied, utilisation of inpatient care due to RA decreased in terms of numbers of patients, admissions and hospital days ( Table 2 
Outpatient care
Outpatient care due to RA remained rather unchanged with approximately 90,000 visits and 45,000 patients each year throughout the 2000s.
Sick leave
The number of sick leave days due to RA was halved over the period (Table 3 ). The annual percentage change fluctuated, but there was a downturn by the end of the period. Similar fluctuations and decline of sick leave was simultaneously seen in the general population, but was slightly more pronounced for RA.
Disability pension
The total prevalence of individuals with DPs due to RA declined after the mid-1990s from approximately 10 000 to 7000 (Table 3) 
Costs of RA 1990-2010
The total cost of RA in current prices was doubled between 1990 and 2010 ( Figure 1A) .
Hence, the decreases in healthcare consumption, disability pensions and sick leave due to RA are largely outweighed by price increases (see Supplement 1 for unit prices).
When total fixed costs were calculated to the price level of 2010 using CPI, there was a 32% increase in total fixed costs for RA ( Figure 1B) . The proportion of indirect costs decreased over the years, but still constituted the major part of total costs, with DP as major cost driver. Simultaneously, there was a sharp increase in the amount of direct costs, mainly after the introduction of biological drugs. In the later years, costs for biological drugs made up for an increasing share of total costs. A levelling off of total costs was however observed at the end of the period.
When inflation adjustment was made with the healthcare price index, there was a noticeable downturn in all costs except drug costs from the mid-90s and onwards ( Figure 1C ). This resulted in similar levels of total costs in the beginning and in the end of the period. Hence the increased costs for biological drugs were compensated by decreases in other cost domains. The main cost decreases occurred in indirect costs. Figure 2 shows the proportion of total costs for RA represented by each cost type during the two decades. Drugs increased from 3% to 33% of total costs between 1990 and 2010, while indirect costs decreased from 75% to 57% of total costs. Simultaneously, inpatient care decreased from representing 15% to 3% of total costs.
DISCUSSION
There are a number of previously published cost studies for RA (1-5, 23-27, 29-31, 52-54).
To our knowledge, this is the first study that covers the total costs of RA during 20 years.
The period 1990-2010 was deliberatively chosen to cover 10 years before and 10 years after the introduction of biological drugs. By using national register data, selection bias has been avoided since the entire RA population was covered. We cannot distinguish the causality behind the cost changes but we can present the trajectory of cost development during this extended period. The present study differs from previous studies, which have been based on cohorts and/or examined individual cost items and years.
The various structures of healthcare systems in different countries make plain comparisons between studies difficult. In addition, access to biological drugs differs between countries (32). The present data reflect the development in Sweden and demonstrate that there was a decrease in the utilisation of RA-related inpatient care, as well as sick leave and DP during the two recent decades. Our data confirms previous research (21, 28) , which also exhibited lowered numbers of days on sick leave, with the increased use of biological drugs. The continuous decreases in DP since the 90s are striking, since previous research has found DP either increasing or being stable with the increased use of biological drugs (21, 28) .
However, while the decrease of sick leave in our data accelerated in the mid-2000s, the decrease in DPs started already in the 90s. Likewise, the decrease of inpatient care started in the 1990s and was more pronounced in the 1990s than in the 2000s. It has previously been shown that the number of DPs and sick leave days is correlated with changes in the economic situation in a country, the labour market and the regulatory setting (55). In However, Lundkvist et al. 2008 also included nonmedical costs and costs for informal care in the direct cost calculations, which represented 14% of total costs. In addition, the previous study estimated costs based on three cohort studies that were extrapolated to the national level, in contrast to the present study directly using total national costs for RA.
Our cost estimates are also in accordance with another study based on the Swedish rheumatology quality register estimating a total cost of RA to €524 million in 2009 (31). They are also in line with a previous estimate of the total costs of RA at €367 million in 1997, equivalent to €433 million in 2010 prices (29) .
The choice of inflation adjusting index largely affects the results. Inflation-adjusting total costs with the healthcare price index results in a downward trend for all costs, apart from costs for biological drugs. The difference between the inflation-adjusting indexes is due to a faster price increase in the healthcare sector compared to the rest of the economy. While general prices in Sweden increased by 50% between 1990 and 2010, the nominal wages as well as prices in the labour-intense healthcare sector doubled (+100%).
The healthcare price index gives a result that might be intuitively more appealing since it follows the development in real terms (e.g. inpatient days) to a greater extent than the CPI.
Also, if the only alternative use of resources spent on RA is in the healthcare sector, this result is more relevant. On the other hand, applying a societal perspective, the interesting thing is what the resources spent for RA could buy in any sector of the economy. Then the inflation-adjustment with CPI is more relevant. In addition, adjusting the nominal wages with CPI allows for an increase in inflation-adjusted, or real, annual wages. According to official statistics, real wages have increased by 38% during this period in Sweden. Using the healthcare price index, the whole increase in nominal wages is treated as inflation. In total, this speaks in favor of CPI.
Performing a sensitivity analysis of our results, the total costs increased by 9% at most which indicates robust results (see Supplement 2 for details).
Our study has several limitations. Firstly, some relevant data are lacking. This is the case for care given by the municipalities, informal care and intangible costs. Intangible costs, such as pain and fatigue, are substantial for RA patients, but are difficult to quantify. As a consequence, cost estimates of this kind inevitably underestimate the total effect of the disease on the individual and society. We cannot dismiss the possibility that patients' quality of life may improve with biological drugs, but this has not been within the scope of this study. Secondly, data for outpatient care and sick leave were not complete for all years in the 1990s, and average values were used, leading to possible over-or underestimation of minor importance for the total costs. There is also a risk of overestimation of the role of indirect costs using the human capital method and denying the possible friction in the labour market. Finally, as is always the case with cost of illness studies, it is not possible to state reasons for cost changes or correlation between changes. For example, costs and effects may not be affected only by the introduction of biological drugs but also by the intensification of treatment with traditional DMARDs in the 1990s. • The total fixed cost of RA in Sweden increased by approximately a third between 1990 and 2010.
• The increase was mainly due to increased direct costs after the introduction of biological drugs.
•
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